Multiple Myeloma

  • Cost-Effectiveness of Carfilzomib, Ixazomib, Elotuzumab, or Daratumumab with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in Relapsed/Refractory MM
  • ELOQUENT-2: Extended 4-Year Follow-Up of Elotuzumab plus Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in Relapsed/Refractory MM
  • Trends in Survival and Cost Among US Patients with Multiple Myeloma
  • First-in-Human Study of bb2121 Anti-BCMA CAR T-Cell Therapy for Relapsed/Refractory MM: Updated Results
  • Lenalidomide/Placebo Maintenance After Stem-Cell Transplant for Patients with MM: OS and PFS Adjusted for Treatment Crossover
  • Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in Relapsed/Refractory MM: Efficacy and Safety Update
Chicago, IL—The era of immunotherapy in multiple myeloma is near. Two presentations at ASCO 2017 demonstrated that cellular therapy can steer immune reconstitution against multiple myeloma.
Chicago, IL—In patients with newly diagnosed multiple myeloma, the addition of daratumumab to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (ie, the KRd regimen) is showing promise as a frontline treatment regimen. According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd regimen was well-tolerated, and the overall safety profile was consistent with previous reports for KRd, with no additional toxicity observed with the addition of daratumumab. Moreover, the study investigators reported that the regimen was very effective, with 100% overall response rate observed.
San Diego, CA—The addition of venetoclax (Venclexta) to bortezomib (Velcade) and dexamethasone yields high response rates in patients with relapsed or refractory multiple myeloma, especially in patients with disease that is not refractory to bortezomib and who received 1 to 3 previous lines of therapy, according to findings presented by Philippe Moreau, MD, Department of Hematology, Nantes University Hospital, France, at the 2016 American Society of Hematology meeting.
San Diego, CA—Nelfinavir (Viracept), a drug used for HIV, led to a surprisingly high response rate when added to bor­tezomib (Velcade) in patients with proteasome inhibitor–refractory multiple myeloma, according to a phase 2 study reported by Christoph Driessen, MD, myeloma specialist, Kantonsspital St. Gallen, Switzerland, at the 2016 American Society of Hematology meeting.
San Diego, CA—High response rates with the combination of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone in the treatment of patients with high-risk smoldering multiple myeloma suggest that early intervention may be worthwhile in this patient population, based on results from a phase 2 study, said Irene M. Ghobrial, MD, Attending Physician, Medical Oncology, Dana-Farber Cancer Institute, Boston, at the 2016 American Society of Hematology meeting.
  • Adding Daratumumab to Lenalidomide and Dexamethasone in Previously Treated Patients with Relapsed or Refractory Multiple Myeloma Improves Outcomes
  • Real-World Evidence Regarding Newer Treatment Options, Overall Survival, and Healthcare Costs in Patients with Multiple Myeloma
  • Long-Term Analysis of the CASTOR Trial: Adding Daratumumab to Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
  • The Use of Early Response Can Guide Treatment Selection in Patients with Newly Diagnosed Multiple Myeloma
  • Using Montelukast to Reduce Infusion Reactions in Patients with Relapsed or Refractory Multiple Myeloma
Since the “War on Cancer” was declared in 1971, advances in cancer treatment and prevention have accomplished considerable success in reducing mortality and morbidity in many tumor types, and more Americans than ever are surviving cancer.

Adding the recently approved daratumumab (Darzalex), a human, CD38-directed monoclonal antibody, to a standard regimen of bortezomib (Velcade) and dexamethasone improved progression-free survival (PFS) by >60% compared with the standard regimen in patients with relapsed or refractory multiple myeloma, according to Antonio Palumbo, MD, Chief of the Multiple Myeloma Unit, University of Torino, Italy.

Interim results from a phase 1b study indicate that the investigational monoclonal antibody isatuximab, in combination with lenalidomide and dexamethasone, achieves responses in >50% of patients with relapsed or refractory multiple myeloma, including those with disease refractory to immunomodulatory drugs (IMiDs).

Page 1 of 4
Results 1 - 10 of 39
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME